• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Accuray Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    11/25/24 4:05:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email
    8-K
    false000113872300011387232024-11-212024-11-21

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 21, 2024

    ACCURAY INCORPORATED

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-33301

    20-8370041

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1240 Deming Way

     

    Madison, Wisconsin

     

    53717-1954

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 608 824-2800

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share

    ARAY

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (a)
    Amended and Restated 2016 Equity Incentive Plan

    At the Annual Meeting of Stockholders of Accuray Incorporated (the “Company”) held on November 21, 2024 (the “2024 Annual Meeting”), the Company’s stockholders approved amending and restating the Company’s 2016 Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance thereunder by 5,000,000 shares. A description of the Amended and Restated 2016 Equity Incentive Plan is set forth in the Company’s definitive proxy statement on Form 14A filed with the United States Securities and Exchange Commission on October 4, 2024 and is qualified in its entirety by reference to the full text of the Amended and Restated 2016 Equity Incentive Plan, a copy of which is being filed as Exhibit 10.1 to this Form 8-K.

     

    (b)
    Amended and Restated 2007 Employee Stock Purchase Plan

     

    At the 2024 Annual Meeting, the Company’s stockholders also approved amending and restating the Company’s Amended and Restated 2007 Employee Stock Purchase Plan to increase the number of shares of the Company’s common stock that may be issued thereunder by 2,500,000 shares. A description of the Amended and Restated 2007 Employee Stock Purchase Plan is set forth in the 2024 Proxy Statement and is qualified in its entirety by reference to the full text of the Amended and Restated 2007 Employee Stock Purchase Plan, a copy of which is being filed as Exhibit 10.2 to this Form 8-K.

     

    (c)
    Appointment of Principal Accounting Officer

     

    On November 21, 2024, the Company’s Board of Directors appointed Michael Murphy, 45, as the Company’s principal accounting officer, effective December 2, 2024. Mr. Murphy joined the Company in October 2024 as Vice President, Corporate Controller. Previously, from February 2024 to October 2024, he served as Vice President, Chief Accounting Officer and Treasury at Duluth Trading Company, an American workwear and accessories company, where he also served as Interim Chief Financial Officer, Vice President and Chief Accounting Officer from September 2023 to February 2024, Vice President and Chief Accounting Officer from September 2019 to August 2023 and Corporate Controller from December 2018 to September 2019. Prior to that, he served as Chief Accounting Officer at First Business Financial Services, Inc., a financial services company, from September 2015 to December 2018. Mr. Murphy began his career at KPMG LLP. Mr. Murphy received a Bachelor of Business Administration, Accounting and Finance as well as a Master of Accountancy, both from the University of Wisconsin-Madison.

     

    In connection with his appointment, Mr. Murphy will enter into the Company's standard indemnification agreement. Mr. Murphy will not receive any additional compensation in connection with her appointment. Mr. Murphy has no family relationships or related party transactions with the Company that would require disclosure under Items 401(d) and 404(a) of Regulation S-K in connection with her appointment.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    At the 2024 Annual Meeting, the Company’s stockholders voted on five proposals as set forth below. The following is a brief description of each proposal submitted to a vote at the 2024 Annual Meeting, as well as the number of votes cast for and against, the number of abstentions, and the number of broker non-votes with respect to each proposal.

     

    Proposal No. 1: Election of Directors

     

    The stockholders elected each of the following persons as a Class III director of the Company to hold office until the Company’s 2027 Annual Meeting of Stockholders or until his or her successor is duly elected or appointed.

     

    Nominee

    For

    Against

    Abstain

    Broker Non-Votes

    James M. Hindman

    48,004,871

    6,794,026

    94,739

    23,800,193

    Suzanne Winter

    48,484,848

    3,015,001

    3,393,787

    23,800,193

     

    Proposal No. 2: Approval of Amendment to the Company’s 2016 Equity Incentive Plan

    2

     


     

    The stockholders approved the Company’s Amended and Restated 2016 Equity Incentive Plan, with 48,115,913 shares in favor, 6,656,453 shares against, 121,270 shares abstaining and 23,800,193 broker non-votes.

    Proposal No. 3: Approval of Amendment to the Company’s 2007 Employee Stock Purchase Plan

    The stockholders approved the Company’s Amended and Restated 2007 Employee Stock Purchase Plan, with 50,239,197 shares in favor, 4,541,642 shares against, 112,797 shares abstaining and 23,800,193 broker non-votes.

     

    Proposal No. 4: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

     

    The stockholders cast an advisory vote to approve the compensation of the Company’s named executive officers as follows: 50,868,587 shares in favor, 3,697,761 shares against, 327,288 shares abstaining and 23,800,193 broker non-votes.

     

    Proposal No. 5: Ratification of Independent Registered Public Accounting Firm

     

    The stockholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2025, with 76,205,166 shares in favor, 2,271,887 shares against, 216,776 shares abstaining and no broker non-votes.

     

     

     

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No. Description

    10.1 Accuray Incorporated Amended and Restated 2016 Equity Incentive Plan and forms of award agreements thereunder

    10.2 Accuray Incorporated Amended and Restated 2007 Employee Stock Purchase Plan

    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

    3

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ACCURAY INCORPORATED

     

    Dated: November 25, 2024

    By:

    /s/ Jesse Chew

    Jesse Chew

    Senior Vice President, Chief Legal Officer & Corporate Secretary

     

     

     

    4


    Get the next $ARAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      5/30/24 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

      SC 13G/A - ACCURAY INC (0001138723) (Subject)

      9/6/24 9:00:07 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Accuray Incorporated

      SC 13G - ACCURAY INC (0001138723) (Subject)

      2/13/24 4:56:01 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

      SC 13G/A - ACCURAY INC (0001138723) (Subject)

      2/13/24 11:19:22 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, Chief Operations Officer Peralta Leonel

      4 - ACCURAY INC (0001138723) (Issuer)

      3/3/25 5:41:56 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Peralta Leonel

      3 - ACCURAY INC (0001138723) (Issuer)

      2/13/25 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SVP Chief Financial Officer Pervaiz Ali covered exercise/tax liability with 2,013 shares, decreasing direct ownership by 0.55% to 362,231 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      1/2/25 5:32:36 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Financials

    Live finance-specific insights

    See more
    • Accuray Reports Fiscal 2025 Third Quarter Financial Results

      MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025. Key Fiscal Third Quarter Highlights: Total net revenue was $113.2 million, an increase of 12 percent year-over-yearNet loss was $1.3 million compared to a net loss of $6.3 million in the prior year periodAdjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the

      4/30/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025

      MADISON, Wis., April 16, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2025, ended March 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 30, 2025. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa

      4/16/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

      MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2024. Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidanceTotal net revenue was $116.2 million, an increase of 8 percent year-over-yearNet income was $2.5 million compared to a net loss of $9.6 million in the prior year periodAdjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period"Our strong Q2 performance reflects outstanding execution of our str

      2/5/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

      More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body r

      5/7/25 7:35:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

      Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis., May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy. The CyberKnife Center Salzburg's team used the Accuray CyberComm™ technology to commission their system, the latest-generation CyberKnife S

      5/5/25 4:10:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Reports Fiscal 2025 Third Quarter Financial Results

      MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025. Key Fiscal Third Quarter Highlights: Total net revenue was $113.2 million, an increase of 12 percent year-over-yearNet loss was $1.3 million compared to a net loss of $6.3 million in the prior year periodAdjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the

      4/30/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Leonel Peralta to Join Accuray as Chief Operations Officer

      MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has

      1/21/25 9:15:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Appoints Michael Murphy as VP, Corporate Controller

      MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024

      10/21/24 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Robert C. Kill Joins Accuray Board of Directors

      SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie

      2/1/23 4:10:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Accuray Incorporated

      10-Q - ACCURAY INC (0001138723) (Filer)

      5/2/25 4:05:24 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ACCURAY INC (0001138723) (Filer)

      4/30/25 4:10:13 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ACCURAY INC (0001138723) (Filer)

      2/7/25 4:01:08 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Accuray with a new price target

      ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

      2/13/24 6:29:42 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Accuray with a new price target

      B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      6/23/22 7:25:39 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on Accuray with a new price target

      Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      12/22/21 4:56:14 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care